Research guide / Tirzepatide

What is Tirzepatide? A Complete Research Guide.

Updated August 2026 · 12 minute read

Tirzepatide is a peptide that activates two incretin hormone receptors in one molecule. This guide separates what peer-reviewed studies show from what registries record and what regulators have actually approved.

Research information only. This article summarises published and registered research. It is not medical advice, a dosing guide, or a recommendation to use any product. Trial averages do not predict an individual outcome, and approved medicines are available only through licensed prescribers and pharmacies.

01 / Overview

What is tirzepatide?

Tirzepatide, developed by Eli Lilly under the code LY3298176, is a long-acting peptide that activates the receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in a single molecule.[1]

Because it acts at two incretin receptors, it is often called a dual agonist or 'twincretin'. That description refers to its pharmacology; it says nothing by itself about who should use it or under what conditions.

Tirzepatide has one of the largest clinical datasets of any incretin-based compound, spanning type 2 diabetes (the SURPASS programme), obesity (the SURMOUNT programme), heart failure with preserved ejection fraction (SUMMIT), and cardiovascular outcomes (SURPASS-CVOT). Unlike newer investigational agents such as retatrutide, tirzepatide has completed regulatory review in several jurisdictions.

View the Tirzepatide research listing

02 / Mechanism

How does tirzepatide work?

Tirzepatide is designed to bind to and activate two receptors involved in nutrient sensing and glucose regulation. It is a single peptide engineered to act at both, rather than a combination of two drugs.[1], [2]

Pathway	Normal signalling role	Research relevance
GLP-1 receptor	Participates in glucose-dependent insulin signalling, satiety signalling, and gastric function.	A well-studied incretin target; tirzepatide combines it with GIP receptor activity in one molecule.
GIP receptor	Participates in nutrient-responsive, glucose-dependent insulin signalling.	Its addition distinguishes tirzepatide from single GLP-1 agonists such as semaglutide; researchers are examining how the combined activity shapes metabolic outcomes.
Glucagon receptor	Participates in hepatic glucose regulation and energy metabolism.	Tirzepatide does not target this receptor — that is the key pharmacological difference from the investigational triple agonist retatrutide.

The working hypothesis is that GLP-1 receptor activity influences appetite, gastric emptying, and glucose-dependent insulin secretion, while GIP receptor activity may complement these effects and influence how the body handles nutrients. The precise contribution of each pathway to the outcomes seen in trials cannot be separated within those studies and should not be treated as settled.

03 / Published evidence

Peer-reviewed findings

In the 40-week SURPASS-2 Phase 3 trial, 1,879 adults with type 2 diabetes were randomised to tirzepatide 5, 10, or 15 mg or semaglutide 1 mg. Mean HbA1c change was −2.01, −2.24, and −2.30 percentage points across the tirzepatide groups versus −1.86 with semaglutide; all tirzepatide doses were noninferior and superior. Body-weight reductions were also greater with tirzepatide (estimated differences of −1.9 to −5.5 kg). These are group averages from a controlled trial, not expected individual results.[1]

In the 72-week SURMOUNT-1 Phase 3 trial, 2,539 adults with obesity or overweight (without diabetes) were randomised to tirzepatide 5, 10, or 15 mg or placebo. Mean weight change at week 72 was −15.0%, −19.5%, and −20.9% versus −3.1% with placebo, and 85–91% of tirzepatide participants lost at least 5% of body weight versus 35% with placebo.[2]

In the SUMMIT trial, 731 patients with heart failure with preserved ejection fraction and obesity were randomised to tirzepatide (up to 15 mg) or placebo. Over a median 104 weeks, cardiovascular death or a worsening heart-failure event occurred in 9.9% of the tirzepatide group versus 15.3% with placebo (hazard ratio 0.62).[3]

In SURPASS-CVOT, 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease were randomised to tirzepatide or dulaglutide. The primary composite of cardiovascular death, myocardial infarction, or stroke occurred in 12.2% versus 13.1% (hazard ratio 0.92), meeting the prespecified noninferiority margin against an active comparator with established cardiovascular benefit.[4]

04 / Trial registry

Registered clinical programme

A registry record shows what a study was designed to test and its reported recruitment status. It does not by itself establish efficacy, safety, or approval.

Programme	Trial ID	Population	Registry status
SURMOUNT-1	NCT04184622	Obesity or overweight, without type 2 diabetes	Completed · 2,539 participants
SUMMIT	NCT04847557	Heart failure with preserved ejection fraction and obesity	Completed · 731 participants
SURPASS-CVOT	NCT04255433	Type 2 diabetes with atherosclerotic cardiovascular disease	Completed · 13,299 participants

Statuses and enrolment figures reflect the original ClinicalTrials.gov records reviewed for this August 2026 update. Registry records can change.[5], [6], [7]

Afiya Labs lists a Tirzepatide reference material for laboratory research. The catalogue entry is not a medicine listing and is not presented as suitable for human use.

See the Tirzepatide catalogue entry

Shop Tirzepatide pen

05 / Safety evidence

What safety findings have trials reported?

In SURPASS-2, the most common adverse events were gastrointestinal and primarily mild to moderate: nausea in 17–22% of tirzepatide participants (18% with semaglutide), diarrhea in 13–16% (12%), and vomiting in 6–10%.[1]

In SURMOUNT-1, gastrointestinal events were again the most common, occurred mostly during dose escalation, and were primarily mild to moderate. Approved prescribing information for Mounjaro and Zepbound carries a boxed warning about thyroid C-cell tumours seen in rodent studies and lists contraindications and precautions that only a prescriber can apply.[2]

Controlled trials cannot answer every long-term safety question. Findings depend on the studied population, follow-up period, and dose-escalation design. Anyone considering an approved tirzepatide medicine should rely on its official prescribing information and a licensed clinician, not a research summary.

06 / Regulators

Approval status in the US, Europe, and UAE

United States

Tirzepatide is FDA-approved under two brand names: Mounjaro (13 May 2022) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and Zepbound (8 November 2023) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Separately, the FDA has published concerns about unapproved and compounded GLP-1 products, which are not the same as the approved medicines.[8], [9], [10]

European Union

Tirzepatide is authorised in the EU under the brand name Mounjaro, following a positive EMA assessment in 2022. A marketing authorisation applies only to the assessed product, its approved indications, and its official labelling — not to other materials sold under the same molecule name.[9]

United Arab Emirates

The Emirates Drug Establishment maintains the UAE's public registered medical product directory. We did not rely on a directory search to infer approval, non-approval, legality, availability, or permission for use of any specific product; those questions require confirmation from the EDE. Approved medicines in the UAE are dispensed through licensed channels.[11]

07 / Quick answers

Frequently asked questions

Is tirzepatide an approved medicine?

Yes, in several jurisdictions under specific brand names and indications — Mounjaro and Zepbound in the US, and Mounjaro in the EU. Approval applies to those assessed products only, through licensed prescribers and pharmacies; it does not extend to research or compounded materials.

Why is it called a dual agonist?

It activates two incretin receptor families in one molecule: GIP and GLP-1. The term describes its pharmacology, not a dosing or usage recommendation.

How does tirzepatide differ from semaglutide?

Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide also activates the GIP receptor. In the head-to-head SURPASS-2 trial, tirzepatide produced greater average HbA1c and weight reductions than semaglutide 1 mg over 40 weeks.

How does it differ from retatrutide?

Retatrutide is an investigational triple agonist that adds glucagon-receptor activity to GIP and GLP-1. Unlike tirzepatide, retatrutide has not completed regulatory review and is not an approved medicine.

What side effects were seen in trials?

Gastrointestinal events — nausea, diarrhea, and vomiting — were the most common in the cited trials, mostly mild to moderate and concentrated during dose escalation. Approved products carry a boxed warning about rodent thyroid C-cell tumour findings; full safety information lives in the official prescribing information.

What does the UAE directory show?

It is a public register of medical products. This guide does not turn a directory search result — or the absence of one — into a claim about approval, legality, or permitted use. The EDE is the appropriate authority for a current determination.

08 / Sources